Brun Scott C. 4

What Happened Scott C. Brun, a director of Forte Biosciences, was granted 18,353 restricted stock units (RSUs) on 2026-05-29. The RSUs were issued at $0.00 (no cash paid) and are reported as a derivative award—there is no immediate cash value until the RSUs convert to shares upon vesting. This is a grant/compensation event, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-29; filing date: 2026-06-02 (filed within the standard two-business-day Form 4 deadline).
• Grant: 18,353 RSUs; acquisition price reported as $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each RSU equals a contingent right to one share of common stock. F2 — 100% of the RSUs vest on the date of the first annual meeting of stockholders occurring after May 29, 2026, subject to the reporting person’s continued service.
• Classification: Derivative award (code A on Form 4).

Context RSU grants are a common form of equity compensation for directors and employees and do not represent an immediate purchase or sale of shares. They only convert into actual shares (and thus market exposure or proceeds) if and when they vest and are delivered. This filing simply notifies investors of the grant and the stated vesting condition; it does not indicate that shares were sold or bought in the market.